AVADEL PHARMACEUTICALS PLC (AVDL)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net product revenue | 68,129 | 52,511 | 50,025 | 41,504 |
| Cost of products sold | 6,366 | 5,577 | 6,155 | 2,788 |
| Gross profit | 61,763 | 46,934 | 43,870 | 38,716 |
| Selling, general and administrative expenses | 48,624 | 45,581 | 40,394 | 47,406 |
| Research and development expenses | 4,255 | 4,354 | 3,803 | 4,051 |
| Total operating expense | 52,879 | 49,935 | 44,197 | 51,457 |
| Operating income (loss) | 8,884 | -3,001 | -327 | -12,741 |
| Investment and other (expense) income, net | -34 | 397 | 610 | 1,126 |
| Interest expense | 2,355 | 2,238 | 2,820 | 2,716 |
| Income (loss) before income taxes | 6,495 | -4,842 | -2,537 | -14,331 |
| Income tax benefit | -3,170 | 78 | 88 | -509 |
| Net income (loss) | 9,665 | -4,920 | -2,625 | -13,822 |
| Net income (loss) per share - basic (in dollars per share) | 0.1 | -0.05 | -0.03 | -0.14 |
| Net income (loss) per share - diluted (in dollars per share) | 0.1 | -0.05 | -0.03 | -0.14 |
| Weighted average number of shares outstanding - basic (in shares) | 96,726,000 | 96,601,000 | 96,300,000 | 96,151,000 |
| Weighted average number of shares outstanding - diluted (in shares) | 99,087,000 | 96,601,000 | 96,300,000 | 96,151,000 |